Vaxcyte Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-766.6M | $-463.9M | $-402.3M | $-223.5M | $-100.1M | $-89.2M | $-50.3M | $-29.5M |
| Depreciation & Amortization | $16.4M | $7.0M | $3.2M | $2.8M | $1.8M | $1.4M | $1.2M | $1.0M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $138.8M | $84.8M | $48.8M | $23.7M | $10.7M | $5.4M | $1.2M | $749.0K |
| Net Cash from Operating Activities | $-655.6M | $-452.6M | $-296.8M | $-170.6M | $-121.4M | $-46.6M | $-47.1M | $-30.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $13.7M | $22.4M | $16.1M | $5.8M | $6.6M | $1.2M | $1.2M | $1.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $437.4M | $-2.01B | $-773.3M | $74.6M | $-212.3M | $-1.1M | $-1.2M | $-1.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $2.0M | $2.45B | $639.8M | $861.5M | $17.8M | $374.9M | $41.6M | $62.2M |
| Net Change in Cash | $-213.8M | $-9.4M | $-437.0M | $765.7M | $-316.3M | $327.2M | $-7.1M | $30.0M |
| Free Cash Flow | $-669.3M | $-475.1M | $-312.9M | $-176.4M | $-127.9M | $-47.8M | $-48.3M | $-32.2M |